Tumor CD19 Expression Determines Distinct Clinical Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma
Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei et autres
0 citationsBlood Cancer Discovery
Lorenzo Falchi
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
342Publications signalées
3821Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCAR-T cell therapy researchCNS Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research
Publications récentes
Lenalidomide and rituximab for relapsed/refractory follicular lymphoma: a systematic review and meta-analysis
Sarah Matarasso Greenfeld, Rakan Okde, Mark Sorin, Olivia Benguigui et autres
0 citationsBlood Cancer Journal
Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial
Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua Brody et autres
0 citationsBlood
First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma
Umberto Vitolo, Lorenzo Falchi, Per‐Ola Andersson, Marcel Nijland et autres
1 citationHemaSphere
IBCL-1332: Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab With Lenalidomide and Rituximab vs Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
Bradley D. Hunter, Lorenzo Falchi, Marcel Nijland, Huiqiang Huang et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
ABCL-619: Epcoritamab + Chemoimmunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Pooled Results From Arms 4 and 10 of EPCORE NHL-2
Yasmin Karimi, Pau Abrisqueta, Charalambos Andreadis, Chan Y. Cheah et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-619: Epcoritamab + Chemoimmunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Pooled Results From Arms 4 and 10 of EPCORE NHL-2
Yasmin Karimi, Pau Abrisqueta, Charalambos Andreadis, Chan Y. Cheah et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-1506: Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment Effect of Epcoritamab With Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma
Lorenzo Falchi, Marcel Nijland, Kim Linton, Neta Goldschmidt et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
ORAL ABSTRACT: IBCL-1332: Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab (E) With Lenalidomide and Rituximab (R2) Versus R2 for Relapsed or Refractory Follicular Lymphoma (R/R FL)
Bradley D. Hunter, Lorenzo Falchi, Marcel Nijland, Huiqiang Huang et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-1332: Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab With Lenalidomide and Rituximab vs Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
Bradley D. Hunter, Lorenzo Falchi, Marcel Nijland, Huiqiang Huang et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
IBCL-1346: Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab in EPCORE FL-1 vs Real-World Chemoimmunotherapy in Relapsed/Refractory Follicular Lymphoma
Habte Yimer, Lorenzo Falchi, Rong Tao, Loic Ysebaert et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-1346: Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab in EPCORE FL-1 vs Real-World Chemoimmunotherapy in Relapsed/Refractory Follicular Lymphoma
Habte Yimer, Lorenzo Falchi, Rong Tao, Loic Ysebaert et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.